Barton Jennifer L
Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Patient Prefer Adherence. 2009 Nov 29;3:335-44. doi: 10.2147/ppa.s5835.
Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1% of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA.
在过去十年中，随着生物疗法（如肿瘤坏死因子抑制剂）的引入，类风湿关节炎（RA）的治疗取得了重大进展。使用这些药物后，许多类风湿关节炎患者的症状、功能和生活质量都有了显著改善。然而，随着生物制剂的引入，对于这种影响多达1%人口的慢性疾病的决策变得更加复杂。患者对给药方式和频率、特定风险与益处以及用药观念的偏好对于这些药物的接受和依从性至关重要。本综述考察了目前关于类风湿关节炎患者对生物疗法的满意度、依从性和偏好的文献。
